Chugai's HEMLIBRA® Receives Regulatory Approval from U.S. FDA for Hemophilia A Without Inhibitors
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA® (US generic name: emicizumab-kxwh), a treatment for hemophilia A created by Chugai, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks. The FDA has also approved additional dosing options of every two weeks or every four weeks in adults and children with hemophilia A with factor VIII inhibitors. The US application was submitted by Genentech, a member of Roche Group.
“We are very pleased that HEMLIBRA has obtained its first regulatory approval for people with hemophilia A without inhibitors,” said Chugai’s President & CEO, Tatsuro Kosaka. “Now people with hemophilia A in the US can be offered flexibility in HEMLIBRA’s dosing interval from multiple options depending on their needs, regardless of their inhibitor expression. We anticipate that HEMLIBRA will make an even greater contribution to the advancement of treatment of hemophilia A.”
This regulatory approval is based on results from two Phase lll studies HAVEN 3 (NCT02847637) and HAVEN 4 (NCT03020160), conducted jointly with Roche and Genentech. HAVEN 3 study was conducted to evaluate the reduction of bleed rate of HEMLIBRA subcutaneous injection once a week and once every two weeks in people with hemophilia A (12 years of age or older) without inhibitors to factor VIII. HAVEN 4 study was conducted to evaluate efficacy, safety, and pharmacokinetics of HEMLIBRA subcutaneous injection every four weeks in people with hemophilia A (12 years of age or older), with and without inhibitors to factor VIII.
HEMLIBRA was granted Priority Review and Breakthrough Therapy Designation by the FDA in hemophilia A without inhibitors, following the prior designations in hemophilia A with inhibitors. Priority Review designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease. In Japan and the EU, applications have been filed to regulatory authorities and are currently under review for an additional indication of prophylactic treatment for people with hemophilia A without inhibitors, as well as for additional dosage and administration as a biweekly or every four-week treatment for people with hemophilia A with inhibitors to factor VIII.
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2017 of Chugai totalled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.
Trademarks used or mentioned in this release are protected by law.
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Libelium Integrates Radar Technology with its IoT Devices for Smart Parking Applications27.5.2019 11:00:00 EEST | Tiedote
Aiming to meet the growing demand for greater precision in smart parking devices, Libelium, the Spanish manufacturer of hardware and IoT solutions, has integrated radar technology in detecting the availability of parking spaces. The new Smart Parking node improves detection and stability performance thanks to a radar sensor which allows precise detection (99%) of vehicles parked over the device that sends the data to the cloud through the LoRaWAN network. IoT technology applied to the detection of parking places can reduce traffic, save fuel, decrease CO 2 emissions and improve the driving experience and habitability of cities. In addition, smart parking devices are being highly demanded by municipalities to check rotation levels in restricted parking areas (taxis, loading and unloading, recharging electric vehicles and disabled areas). First real deployment is already taking place in the city of Huesca (Northern Spain) where 190 nodes are being installed to detect the occupation of pa
Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Shown in a Recent Study to Have Beneficial Effects on Human Health and Well-being27.5.2019 11:00:00 EEST | Tiedote
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced the results of a recent study conducted by Dr. Octavio L. Perez, adjunct researcher in Integrative Lighting at Mount Sinai Hospital in NYC, NY, USA on the non-visual melanopic stimulus of LED sources. The study showed that the company’s SunLike Series natural spectrum LEDs provide up to 21% more melanopic stimulus than conventional LEDs at 4000K, and the same melanopic stimulus as daylight at 6500K (D65). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190527005028/en/ Seoul Semiconductor's SunLike Series Natural Spectrum LEDs (Graphic: Business Wire) In addition to the visual effects of light and lighting on people, such as visual acuity and color fidelity, there are also non-visual effects. These non-visual effects can affect human health and well-being in aspects related to sleep, awakeness, alertness, circad
2019 Trends to Watch in PV Market: High-efficiency Module27.5.2019 10:00:00 EEST | Tiedote
Upon the return of SNEC PV Power Expo next month, PV InfoLink will explore the PV product trends and the transition of module output at a seminar held in Shanghai on June 3. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190527005064/en/ China's Export Destinations and Share of Special Module Exports (Graphic: Business Wire) Titled “2H19 PV Market Outlook and Forecast,” the seminar will feature topics spanning China’s transition to subsidy-free market, PV market outlook and supply chain. PV InfoLink, a leading solar market research firm and host of the seminar, has invited top-tier companies including Jinko, Longi, and GCL-Si to discuss the major issues. As the global PV market grows continuously, China’s module exports had hit a record high of 16 GW in Q1’19, a significant growth from last Q4’s 12 GW. In addition to India and Japan’s traditional high season, China exported 5 GW of modules to the European markets in Q1. Foll
A.P. Moller - Maersk Will Join Traxens27.5.2019 09:30:00 EEST | Tiedote
Traxens, a company providing high-value data and services for the supply chain industry, and A.P. Moller - Maersk (“Maersk”), the integrated container logistics company, today announced that Maersk will be joining CMA CGM and MSC Mediterranean Shipping Company as a key shareholder and customer of Traxens. Founded in 2012, Traxens has been developing unique solutions for the cargo logistics arena and has created an innovative container monitoring and coordination solution. CMA CGM first invested in the startup in 2012 and was later joined in 2016 by MSC. A milestone in the development of Traxens The agreement will see Maersk invest capital in Traxens, in which it will have similar shareholder rights as CMA CGM and MSC. Maersk also commits to order up to 50,000 Traxens devices, a similar order to those placed earlier by CMA CGM and MSC. Traxens can now further focus on strengthening its solution and drive interoperability based on non-proprietary technologies and open standards. The deve
TYAN Showcases HPC, Storage and Cloud Server Platforms Featuring 2nd Gen Intel® Xeon® Scalable Processors at Computex 201927.5.2019 05:00:00 EEST | Tiedote
TYAN®, an industry-leading server platform design manufacturer and a subsidiary of MiTAC Computing Technology Corporation, will be exhibiting a full line of HPC, storage and cloud computing server platforms that are optimized for HPC, enterprise and datacenter markets at Computex 2019 from May 28th to June 1st, Booth # L0631a in Taipei, Taiwan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005002/en/ TYAN's HPC, Storage and Cloud Computing Server Platforms are Optimized for HPC, Enterprise and Data Center Markets to Deliver Leading Performance (Photo: Business Wire) “The increasingly growing demand for AI is transforming the data center and is resulting in a tremendous amount of data being pulled into big data platforms at massive scale,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's TYAN Business Unit. “TYAN’s leading portfolio of HPC, storage and cloud server platforms are based on the 2
Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science26.5.2019 10:00:00 EEST | Tiedote
Nanopharmaceutics promises ground-breaking innovation in the development of medicines: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005014/en/ The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the University of Basel The commitment by Vifor Pharma and the University of Basel is aimed at ensuring Switzerland has the specialist knowledge and equipment needed to compete globally in this important emerging area of life sciences With this decision, Vifor Pharma is demonstrating its commitment to Switzerland as a world-leading location for pharmaceutical research and development Nanomedicines are playing an increasingly important role in the development of innovative new medications. These drugs are able to overcome specific cellular barriers in the human body with a view to targeting their effect even more precisely. Nanopharmacy therefore promises to help advance medic
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme